Sotrastaurin

Description	Sotrastaurin, a first-in-class protein kinase C (PKC) inhibitor, is aiming to become the first oral treatment that inhibits T-cell activation since the introduction of calcineurin inhibitors. T-cell activation is an early step in autoimmune diseases such as psoriasis and is also essential for the rejection of transplanted organs. Sotrastaurin blocks a pathway critical to T-cell activation and has shown promise in organ transplantation as well as in autoimmune disorders. Sotrastaurin is developed
Pathways	TGF beta/Smad Epigenetics
Targets	PKC

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.